SCHEMBL384385

SCHEMBL384385

CCOC(=O)c1cc2cc(OC(F)(F)F)ccc2[nH]1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.74
ALDH1A1 P00352 3/20 0.74
HPGD P15428 3/20 0.74
RAB9A P51151 3/20 0.74
NPC1 O15118 2/20 0.74
LMNA P02545 2/20 0.74
HTT P42858 1/20 0.74
L3MBTL1 Q9Y468 1/20 0.74
SMN1; SMN2 Q16637 2/20 0.67
GAA P10253 2/20 0.67
KMT2A Q03164 2/20 0.67
HSD17B10 Q99714 1/20 0.67
HRH3 Q9Y5N1 1/20 0.62
MAPT P10636 2/20 0.61
MEN1 O00255 1/20 0.61
GLA P06280 1/20 0.61
ATM Q13315 1/20 0.61
MMP13 P45452 7/20 0.61
MMP2 P08253 5/20 0.61
MMP14 P50281 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3571495 0.90 MMP13 (0.69) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL2391276 0.85 KDM4E (0.67) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL9263164 0.85 KDM4E (0.80) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL75327 0.85 KDM4E (1.00) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL6518676 0.85 KDM4E (0.71) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL31287683 0.84 KDM4E (0.66) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL22529432 0.83 KDM4E (0.69) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL12423015 0.83 KDM4E (0.65) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL926927 0.83 KDM4E (0.68) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL5680973 0.83 KDM4E (0.76) KDM4EALDH1A1HPGDRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4363403-B1 PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL)PHENYL)AMINO)-1-(1H-INDOL-3-YL)ETHENONE DERIVATIVES UNIV LEUVEN KATH (BE) 2026-05-27 EP disclosed
US-20240308959-A1 PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3 -METHOXY-5-(M ETHYLSULFONYL)PHENYL)AMINO)-1 -(1H-INDOL-3-YL)ETHENONE DERIVATIVES KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-09-19 US disclosed
CN-117616010-A Process for preparing (S) -2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (1H-indol-3-yl) ketene derivatives 杨森制药公司 2024-02-27 CN disclosed
WO-2023274237-A1 PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL)PHENYL)AMINO)-1 -(1H-INDOL-3-YL)ETHENONE DERIVATIVES Janssen Pharmaceuticals, Inc. (US) 2023-01-05 WO disclosed
EP-3052495-B1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS PFIZER (US) 2019-06-26 EP disclosed
US-9963466-B2 Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists VANDERBILT UNIVERSITY (US) 2018-05-08 US disclosed
US-9963466-B2 Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists VANDERBILT UNIVERSITY (US) 2018-05-08 US disclosed
US-9944634-B2 Pyrazolopyridine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2018-04-17 US disclosed
EP-2914597-B1 PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2017-12-06 EP disclosed
US-20170253617-A1 Substituted 5-Membered Heterocyclic Analogs as Protease Activated Receptor 4 (PAR-4) Antagonists VANDERBILT UNIVERSITY 2017-09-07 US disclosed
US-7384969-B2 N-(1H-indolyl)-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2008-06-10 US disclosed
US-7375226-B2 Bi- and tricyclic substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2008-05-20 US disclosed
EP-1042288-B1 TRIPEPTIDYL PEPTIDASE INHIBITORS INST NAT SANTE RECH MED (FR) 2007-11-07 EP disclosed
EP-1828200-A1 BI- AND TRICYCLIC SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER I (GLYT-1) INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE. F. Hoffmann-Roche AG (CH) 2007-09-05 EP disclosed
US-20070149602-A1 N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2007-06-28 US disclosed
US-20070088071-A1 Acyl indoles, compositions containing such compounds and methods of use MERCK SHARP & DOHME LLC 2007-04-19 US disclosed
WO-2006063709-A1 BI- AND TRICYCLIC SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER I (GLYT-1) INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE F.HOFFMANN-LA ROCHE AG (CH) 2006-06-22 WO disclosed
US-20060128713-A1 (6-Chloro-3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridin-2-yl)-(2-isopropoxy-5-methanesulfonyl-phenyl)-methanone; glyicne transporter 1 (GlyT-1) and N-methyl-D-aspartate (NMDA) receptors inhibitor; psychoses, schizophrenia, attention deficit disorders, Alzheimer's disease; cognition activator HOFFMANN-LA ROCHE INC. 2006-06-15 US disclosed
WO-2004111052-A1 PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR) XENOVA LIMITED (GB) 2004-12-23 WO disclosed
US-6335360-B1 INDOLINE-2-CARBOXYLIC AMIDE DERIVATIVES; OBESITY, EATING AND PSYCHOLOGICAL DISORDERS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253617-A1 Substituted 5-Membered Heterocyclic Analogs as Protease Activated Receptor 4 (PAR-4) Antagonists F2RL3, F2R, F2RL1 KDM4E 1291/4885ALDH1A1 3877/4885HPGD 843/4885
US-20070149602-A1 N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE IDO1, IDO2, NPY5R KDM4E 1182/4885ALDH1A1 1202/4885HPGD 1203/4885
US-20070088071-A1 Acyl indoles, compositions containing such compounds and methods of use GPR119, IAPP, GLP1R KDM4E 1723/4885ALDH1A1 2419/4885HPGD 961/4885
US-20240308959-A1 PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3 -METHOXY-5-(M ETHYLSULFONYL)PHENYL)AMINO)-1 -(1H-INDOL-3-YL)ETHENONE DERIVATIVES HTR3C, CCND3, H1-3 KDM4E 910/4885ALDH1A1 1359/4885HPGD 3444/4885
US-20060128713-A1 (6-Chloro-3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridin-2-yl)-(2-isopropoxy-5-methanesulfonyl-phenyl)-methanone; glyicne transporter 1 (GlyT-1) and N-methyl-D-aspartate (NMDA) receptors inhibitor; psychoses, schizophrenia, attention deficit disorders, Alzheimer's disease; cognition activator GRIN1, GRIA1, GRM1 KDM4E 3326/4885ALDH1A1 941/4885HPGD 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.